

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Noxopharm Limited
ABN	50 608 966 123

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Graham Kelly
Date of last notice	9 August 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	21 December 2018
No. of securities held prior to change	<p><u>DIRECT</u></p> <p>1. 35,000 ordinary shares</p> <p><u>INDIRECT</u></p> <p>Milligene Pty Ltd <The GE & PR Kelly Family Trust></p> <p>1. 31,027,568 ordinary shares (Voluntary escrow up to 8/5/2019)</p> <p>2. 12,075,000 unlisted options \$0.30, expiry 28/2/2021 (Voluntary escrow up to 8/5/2019)</p> <p>Phytose Corporation Limited ATF Boundaryone Superannuation Fund</p> <p>3. 175,000 ordinary shares</p> <p>Bende Holdings Pty Ltd</p> <p>4. 162,635 ordinary shares</p>

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

	<p>Prudence Kelly</p> <p>5. 10,000 ordinary shares</p> <p>6. 12,346 Unlisted Option Expiry, 30/11/2021, Exercisable @ \$1.08, vest if employed at 1 December 2018 - Vested</p> <p>7. 12,346 Unlisted Option Expiry, 30/11/2021, Exercisable @ \$1.08, vest if employed at 1 December 2019</p> <p>8. 12,345 Unlisted Option Expiry, 30/11/2021, Exercisable @ \$1.08, vest if employed at 1 December 2020</p>
Class	<p>9. Unlisted Option Expiry, 21/11/2022, Exercisable @ \$0.62, vest if employed at 21 November 2019</p> <p>10. Unlisted Option Expiry, 21/11/2022, Exercisable @ \$0.62, vest if employed at 21 November 2020</p> <p>11. Unlisted Option Expiry, 21/11/2022, Exercisable @ \$0.62, vest if employed at 21 November 2021</p>
Number acquired	<p>9. 20,833 Unlisted Option Expiry, 21/11/2022, Exercisable @ \$0.62, vest if employed at 21 November 2019</p> <p>10. 20,833 Unlisted Option Expiry, 21/11/2022, Exercisable @ \$0.62, vest if employed at 21 November 2020</p> <p>11. 20,834 Unlisted Option Expiry, 21/11/2022, Exercisable @ \$0.62, vest if employed at 21 November 2021</p>
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change	<p><u>DIRECT</u></p> <p>1. 35,000 ordinary shares</p> <p><u>INDIRECT</u></p> <p>Milligene Pty Ltd <The GE & PR Kelly Family Trust></p> <p>1. 31,027,568 ordinary shares (Voluntary escrow up to 8/5/2019)</p> <p>2. 12,075,000 unlisted options \$0.30, expiry 28/2/2021 (Voluntary escrow up to 8/5/2019)</p>

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

	<p>Phytose Corporation Limited ATF Boundaryone Superannuation Fund 3. 175,000 ordinary shares</p> <p>Bende Holdings Pty Ltd 4. 162,635 ordinary shares</p> <p>Prudence Kelly 5. 10,000 ordinary shares 6. 12,346 Unlisted Option Expiry, 30/11/2021, Exercisable @ \$1.08, vest if employed at 1 December 2018 - Vested 7. 12,346 Unlisted Option Expiry, 30/11/2021, Exercisable @ \$1.08, vest if employed at 1 December 2019 8. 12,345 Unlisted Option Expiry, 30/11/2021, Exercisable @ \$1.08, vest if employed at 1 December 2020 9. 20,833 Unlisted Option Expiry, 21/11/2022, Exercisable @ \$0.62, vest if employed at 21 November 2019 10. 20,833 Unlisted Option Expiry, 21/11/2022, Exercisable @ \$0.62, vest if employed at 21 November 2020 11. 20,834 Unlisted Option Expiry, 21/11/2022, Exercisable @ \$0.62, vest if employed at 21 November 2020</p>
<p>Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Issue of unlisted options under the Noxopharm Limited Employee Equity Plan on 21 December 2018.</p>

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.